Liver TET1 was found to promote metabolic dysfunction-associated steatotic liver disease (MASLD) by regulating CD36 ...

Statin users had a significantly lower 10-year cumulative incidence of hepatocellular carcinoma and hepatic decompensation.

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

New research identifies the liver protein PTPRD as a key regulator of metabolic liver disease. Reduced levels of PTPRD disrupt glucose and lipid metabolism, promote liver fat accumulation, and impair ...

Hepatic fibrosis is a reversible wound healing response characterized by accumulation of extracellular matrix (ECM), or "scar," that follows chronic but not self-limited liver disease. The ECM ...

The hepatic symptoms of Wilson’s disease are diverse, ranging from asymptomatic or accidental liver abnormalities to cirrhosis and acute liver failure, and they can onset at any age. The later the age ...

One study explored the use of statins, a class of medications typically used to lower LDL cholesterol levels to reduce the ...

Machine learning may help identify biomarkers and develop predictive models that could assist in the diagnosis of metabolic ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...